<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">
<pdf2xml producer="poppler" version="23.04.0">
<page number="1" position="absolute" top="0" left="0" height="792" width="612">
	<fontspec id="font0" size="9" family="Arial,Italic" color="#000000"/>
	<fontspec id="font1" size="9" family="Arial" color="#000000"/>
	<fontspec id="font2" size="9" family="Arial,Bold" color="#000000"/>
	<fontspec id="font3" size="7" family="Arial,Italic" color="#000000"/>
	<fontspec id="font4" size="10" family="Giovanni-Book" color="#000000"/>
	<fontspec id="font5" size="7" family="Giovanni-Book" color="#000000"/>
	<fontspec id="font6" size="10" family="Giovanni-BookItalic,Italic" color="#000000"/>
	<fontspec id="font7" size="11" family="GillSans,Bold" color="#000000"/>
<text top="41" left="55" width="122" height="10" font="font0" id="p1_t1" reading_order_no="0" segment_no="0" tag_type="title">Medical Immunology 2005, 4 :4<i>Medical Immunology</i></text>
<text top="41" left="384" width="170" height="10" font="font1" id="p1_t2" reading_order_no="1" segment_no="1" tag_type="text">http://www.medimmunol.com/content/4/1/4</text>
<text top="756" left="508" width="46" height="10" font="font1" id="p1_t3" reading_order_no="105" segment_no="13" tag_type="text">Page 4 of 8<b>4</b></text>
<text top="769" left="432" width="122" height="8" font="font3" id="p1_t4" reading_order_no="106" segment_no="14" tag_type="text">(page number not for citation purposes)</text>
<text top="87" left="55" width="241" height="9" font="font4" id="p1_t5" reading_order_no="2" segment_no="2" tag_type="text">species. AVA does not protect hamsters at all [36]. In mice,</text>
<text top="98" left="55" width="241" height="9" font="font4" id="p1_t6" reading_order_no="3" segment_no="2" tag_type="text">the PGA capsule appears to be the primary virulence fac-</text>
<text top="110" left="55" width="241" height="9" font="font4" id="p1_t7" reading_order_no="4" segment_no="2" tag_type="text">tor, and PA-based vaccines confer only limited protection<i>(page number not for citation purposes)</i></text>
<text top="122" left="55" width="241" height="9" font="font4" id="p1_t8" reading_order_no="5" segment_no="2" tag_type="text">[37]. There is no direct correlation between anti-PA titers<a href="">36]. In</a> mice,</text>
<text top="134" left="55" width="241" height="9" font="font4" id="p1_t9" reading_order_no="6" segment_no="2" tag_type="text">and protection in mice and hamsters [36,37]. In guinea</text>
<text top="145" left="55" width="241" height="9" font="font4" id="p1_t10" reading_order_no="7" segment_no="2" tag_type="text">pigs, AVA provides partial protection [35,38,39], but AVA</text>
<text top="157" left="55" width="241" height="9" font="font4" id="p1_t11" reading_order_no="8" segment_no="2" tag_type="text">appears to be more effective in rabbit and macaque mod-<a href="">37]. Th</a>ere is no direct correlation between anti-PA titers</text>
<text top="169" left="55" width="241" height="9" font="font4" id="p1_t12" reading_order_no="9" segment_no="2" tag_type="text">els [35,40-42]. It is noteworthy that "efficacy", as defined<a href="">[36,37</a>]. In guinea</text>
<text top="181" left="55" width="241" height="9" font="font4" id="p1_t13" reading_order_no="10" segment_no="2" tag_type="text">in these studies, is relative. When macaques were exposed<a href="">tion [35,38,39], but AVA</a></text>
<text top="192" left="55" width="241" height="11" font="font4" id="p1_t14" reading_order_no="11" segment_no="2" tag_type="text">experimentally to doses of up to 900 times the LD 50 , 88–</text>
<text top="204" left="55" width="241" height="9" font="font4" id="p1_t15" reading_order_no="12" segment_no="2" tag_type="text">100% of the animals were protected [31]. However, sim-<a href="">[35,40-42</a>]. It is noteworthy that "efficacy", as defined</text>
<text top="216" left="55" width="241" height="9" font="font4" id="p1_t16" reading_order_no="13" segment_no="2" tag_type="text">ulation studies suggest that a person opening a letter filled</text>
<text top="228" left="55" width="241" height="9" font="font4" id="p1_t17" reading_order_no="14" segment_no="2" tag_type="text">with anthrax spores and standing over it for 10 min could</text>
<text top="239" left="55" width="241" height="9" font="font4" id="p1_t18" reading_order_no="15" segment_no="2" tag_type="text">inhale up to 3,000 times and perhaps as much as 9,000</text>
<text top="251" left="55" width="129" height="11" font="font4" id="p1_t19" reading_order_no="16" segment_no="2" tag_type="text">times the LD 50 for humans [2].</text>
<text top="275" left="55" width="241" height="9" font="font4" id="p1_t20" reading_order_no="17" segment_no="6" tag_type="text">A controlled human trial was conducted in the 1950s with<a href="">d [31]. H</a>owever, sim-</text>
<text top="286" left="55" width="241" height="9" font="font4" id="p1_t21" reading_order_no="18" segment_no="6" tag_type="text">a vaccine similar to AVA but derived from a different</text>
<text top="298" left="55" width="241" height="9" font="font4" id="p1_t22" reading_order_no="19" segment_no="6" tag_type="text">attenuated, non-encapsulated strain of B. anthracis grown</text>
<text top="310" left="55" width="241" height="9" font="font4" id="p1_t23" reading_order_no="20" segment_no="6" tag_type="text">aerobically. In a susceptible population of textile mill</text>
<text top="322" left="55" width="241" height="9" font="font4" id="p1_t24" reading_order_no="21" segment_no="6" tag_type="text">workers in the northeastern states of the US who proc-</text>
<text top="333" left="55" width="241" height="9" font="font4" id="p1_t25" reading_order_no="22" segment_no="6" tag_type="text">essed occasionally contaminated goat hair, vaccination</text>
<text top="345" left="55" width="241" height="9" font="font4" id="p1_t26" reading_order_no="23" segment_no="6" tag_type="text">provided 92.5% protection against cutaneous anthrax<a href="">mans [2].</a></text>
<text top="357" left="55" width="241" height="9" font="font4" id="p1_t27" reading_order_no="24" segment_no="6" tag_type="text">[43,44]. However, no assessment of inhalational anthrax</text>
<text top="369" left="55" width="182" height="9" font="font4" id="p1_t28" reading_order_no="25" segment_no="6" tag_type="text">could be made, because cases were too few.</text>
<text top="392" left="55" width="241" height="9" font="font4" id="p1_t29" reading_order_no="26" segment_no="7" tag_type="text">There are several concerns regarding AVA: (i) It does not</text>
<text top="404" left="55" width="241" height="9" font="font4" id="p1_t30" reading_order_no="27" segment_no="7" tag_type="text">protect all animal hosts against different strains of B.<i>B. anthracis </i></text>
<text top="416" left="55" width="241" height="9" font="font6" id="p1_t31" reading_order_no="28" segment_no="7" tag_type="text">anthracis . AVA or PA-based vaccines in general induce</text>
<text top="427" left="55" width="241" height="9" font="font4" id="p1_t32" reading_order_no="29" segment_no="7" tag_type="text">toxin-neutralizing antibodies. The mechanism underlying</text>
<text top="439" left="55" width="241" height="9" font="font4" id="p1_t33" reading_order_no="30" segment_no="7" tag_type="text">the protective action of PA-based vaccines is unclear. It is</text>
<text top="451" left="55" width="241" height="9" font="font4" id="p1_t34" reading_order_no="31" segment_no="7" tag_type="text">thought that anti-PA vaccines protect the host from intox-</text>
<text top="463" left="55" width="241" height="9" font="font4" id="p1_t35" reading_order_no="32" segment_no="7" tag_type="text">ication and thus allow the immune system to deal with</text>
<text top="474" left="55" width="241" height="9" font="font4" id="p1_t36" reading_order_no="33" segment_no="7" tag_type="text">the organism. However, evidence that primates vaccinated<a href="">43,44]</a>. However, no assessment of inhalational anthrax</text>
<text top="486" left="55" width="241" height="9" font="font4" id="p1_t37" reading_order_no="34" segment_no="7" tag_type="text">with AVA or PA vaccine develop transient episodes of bac-</text>
<text top="498" left="55" width="241" height="9" font="font4" id="p1_t38" reading_order_no="35" segment_no="7" tag_type="text">teremia suggests that vaccination does not prevent the</text>
<text top="510" left="55" width="241" height="9" font="font4" id="p1_t39" reading_order_no="36" segment_no="7" tag_type="text">growth of bacilli. (ii) The administration of AVA is bur-</text>
<text top="521" left="55" width="241" height="9" font="font4" id="p1_t40" reading_order_no="37" segment_no="7" tag_type="text">densome, requiring subcutaneous injections at 0, 2, and 4<i>B.</i></text>
<text top="533" left="55" width="241" height="9" font="font4" id="p1_t41" reading_order_no="38" segment_no="7" tag_type="text">weeks and 6, 12, and 18 months with subsequent yearly<i>anthracis</i></text>
<text top="545" left="55" width="241" height="9" font="font4" id="p1_t42" reading_order_no="39" segment_no="7" tag_type="text">boosters [31,32]. In a field trial of a vaccine similar to</text>
<text top="557" left="55" width="241" height="9" font="font4" id="p1_t43" reading_order_no="40" segment_no="7" tag_type="text">AVA, one case of cutaneous anthrax occurred 5 months</text>
<text top="568" left="55" width="241" height="9" font="font4" id="p1_t44" reading_order_no="41" segment_no="7" tag_type="text">after the initial 3-dose series and just before the scheduled</text>
<text top="580" left="55" width="241" height="9" font="font4" id="p1_t45" reading_order_no="42" segment_no="7" tag_type="text">6-month booster [9]. This case suggests that immunity is</text>
<text top="592" left="55" width="241" height="9" font="font4" id="p1_t46" reading_order_no="43" segment_no="7" tag_type="text">not long-lasting and that frequent boosters may be neces-</text>
<text top="604" left="55" width="241" height="9" font="font4" id="p1_t47" reading_order_no="44" segment_no="7" tag_type="text">sary. (iii) The preparative processing of AVA is crude and</text>
<text top="615" left="55" width="241" height="9" font="font4" id="p1_t48" reading_order_no="45" segment_no="7" tag_type="text">lacks consistency. Furthermore, there are relatively high</text>
<text top="627" left="55" width="241" height="9" font="font4" id="p1_t49" reading_order_no="46" segment_no="7" tag_type="text">rates of local and systemic adverse reactions, likely due to</text>
<text top="639" left="55" width="198" height="9" font="font4" id="p1_t50" reading_order_no="47" segment_no="7" tag_type="text">residual toxicity in AVA or other contaminants.</text>
<text top="663" left="55" width="233" height="10" font="font7" id="p1_t51" reading_order_no="48" segment_no="11" tag_type="title">Improvement: highly purified recombinant PA</text>
<text top="674" left="55" width="241" height="9" font="font4" id="p1_t52" reading_order_no="49" segment_no="12" tag_type="text">The limitations of AVA have raised widespread interest in</text>
<text top="686" left="55" width="241" height="9" font="font4" id="p1_t53" reading_order_no="50" segment_no="12" tag_type="text">developing improved anthrax vaccines consisting of well-<a href="">oosters [31,32</a>]. In a field trial of a vaccine similar to</text>
<text top="698" left="55" width="241" height="9" font="font4" id="p1_t54" reading_order_no="51" segment_no="12" tag_type="text">characterized components. A new generation of vaccines</text>
<text top="709" left="55" width="241" height="9" font="font4" id="p1_t55" reading_order_no="52" segment_no="12" tag_type="text">based on highly purified recombinant PA is currently</text>
<text top="721" left="55" width="241" height="9" font="font4" id="p1_t56" reading_order_no="53" segment_no="12" tag_type="text">being developed and evaluated. There have been numer-<a href="">r [9]. </a>This case suggests that immunity is</text>
<text top="87" left="313" width="241" height="9" font="font4" id="p1_t57" reading_order_no="54" segment_no="3" tag_type="text">ous attempts to establish high-level PA expression systems</text>
<text top="98" left="313" width="241" height="9" font="font4" id="p1_t58" reading_order_no="55" segment_no="3" tag_type="text">based on a variety of organisms, including attenuated</text>
<text top="110" left="313" width="241" height="9" font="font4" id="p1_t59" reading_order_no="56" segment_no="3" tag_type="text">strains of B. anthracis , B. subtilis , B. brevis , Salmonella typh-</text>
<text top="122" left="313" width="241" height="9" font="font6" id="p1_t60" reading_order_no="57" segment_no="3" tag_type="text">imurium , E. coli , viruses, insect cells, and plants [45-50]. In</text>
<text top="134" left="313" width="241" height="9" font="font4" id="p1_t61" reading_order_no="58" segment_no="3" tag_type="text">addition, genetic immunization with DNA encoding for</text>
<text top="145" left="313" width="109" height="9" font="font4" id="p1_t62" reading_order_no="59" segment_no="3" tag_type="text">PA is being explored [51].<b>Improvement: highly purified recombinant PA</b></text>
<text top="169" left="313" width="241" height="9" font="font4" id="p1_t63" reading_order_no="60" segment_no="4" tag_type="text">The highly purified PA vaccines are expected to induce</text>
<text top="181" left="313" width="241" height="9" font="font4" id="p1_t64" reading_order_no="61" segment_no="4" tag_type="text">essentially the same immunity as AVA. While some disad-</text>
<text top="192" left="313" width="241" height="9" font="font4" id="p1_t65" reading_order_no="62" segment_no="4" tag_type="text">vantages of AVA due to its "dirty" preparation may be</text>
<text top="204" left="313" width="241" height="9" font="font4" id="p1_t66" reading_order_no="63" segment_no="4" tag_type="text">overcome, limitations in protection and lack of an</text>
<text top="216" left="313" width="235" height="9" font="font4" id="p1_t67" reading_order_no="64" segment_no="4" tag_type="text">immune memory response may be intrinsic to PA itself.</text>
<text top="239" left="313" width="241" height="9" font="font4" id="p1_t68" reading_order_no="65" segment_no="5" tag_type="text">New strategies are needed for further improvement. One</text>
<text top="251" left="313" width="241" height="9" font="font4" id="p1_t69" reading_order_no="66" segment_no="5" tag_type="text">possibility is that other antigens or cellular immunity in</text>
<text top="263" left="313" width="241" height="9" font="font4" id="p1_t70" reading_order_no="67" segment_no="5" tag_type="text">addition to PA-specific antibodies are required for full</text>
<text top="275" left="313" width="241" height="9" font="font4" id="p1_t71" reading_order_no="68" segment_no="5" tag_type="text">protection in different animal species. This is supported<i>B. anthracis</i></text>
<text top="286" left="313" width="241" height="9" font="font4" id="p1_t72" reading_order_no="69" segment_no="5" tag_type="text">by studies showing that the live veterinary vaccine pro-</text>
<text top="298" left="313" width="241" height="9" font="font4" id="p1_t73" reading_order_no="70" segment_no="5" tag_type="text">vides significantly greater protection against anthrax in<i>B. subtilis</i></text>
<text top="310" left="313" width="241" height="9" font="font4" id="p1_t74" reading_order_no="71" segment_no="5" tag_type="text">experimental animals than does AVA, despite the fact that</text>
<text top="322" left="313" width="241" height="9" font="font4" id="p1_t75" reading_order_no="72" segment_no="5" tag_type="text">it frequently induces lower levels of antibodies to PA<i>B. brevis</i></text>
<text top="333" left="313" width="241" height="9" font="font4" id="p1_t76" reading_order_no="73" segment_no="5" tag_type="text">[33,39,42,52,53]. After a naturally acquired infection, and</text>
<text top="345" left="313" width="241" height="9" font="font4" id="p1_t77" reading_order_no="74" segment_no="5" tag_type="text">depending on when samples are taken, 68–93% of cases<i>Salmonella typh-</i></text>
<text top="357" left="313" width="241" height="9" font="font4" id="p1_t78" reading_order_no="75" segment_no="5" tag_type="text">develop antibodies to PA, 42–55% of cases develop anti-<i>imurium</i></text>
<text top="369" left="313" width="241" height="9" font="font4" id="p1_t79" reading_order_no="76" segment_no="5" tag_type="text">bodies to LF, and antibodies to EF are less frequently</text>
<text top="380" left="313" width="241" height="9" font="font4" id="p1_t80" reading_order_no="77" segment_no="5" tag_type="text">detected [34,54-56]. Interestingly, antibodies to the cap-<i>E. coli</i></text>
<text top="392" left="313" width="241" height="9" font="font4" id="p1_t81" reading_order_no="78" segment_no="5" tag_type="text">sule are detected in 67–94% cases [55,56], whereas no<a href="">ants [45-50]. </a>In</text>
<text top="404" left="313" width="241" height="9" font="font4" id="p1_t82" reading_order_no="79" segment_no="5" tag_type="text">response to the capsule is expected in the vaccinees who</text>
<text top="416" left="313" width="241" height="9" font="font4" id="p1_t83" reading_order_no="80" segment_no="5" tag_type="text">have been vaccinated with AVA or non-encapsulated live<a href="">d [51]</a>.</text>
<text top="427" left="313" width="37" height="9" font="font4" id="p1_t84" reading_order_no="81" segment_no="5" tag_type="text">vaccines.</text>
<text top="451" left="313" width="241" height="10" font="font7" id="p1_t85" reading_order_no="82" segment_no="8" tag_type="title">Further improvement: two-in-one postexposure</text>
<text top="463" left="313" width="126" height="10" font="font7" id="p1_t86" reading_order_no="83" segment_no="8" tag_type="title">antitoxic therapy/vaccine</text>
<text top="474" left="313" width="241" height="9" font="font4" id="p1_t87" reading_order_no="84" segment_no="9" tag_type="text">Post-exposure vaccination is the most likely scenario,</text>
<text top="486" left="313" width="241" height="9" font="font4" id="p1_t88" reading_order_no="85" segment_no="9" tag_type="text">given the rarity of natural inhalational anthrax infection.</text>
<text top="498" left="313" width="241" height="9" font="font4" id="p1_t89" reading_order_no="86" segment_no="9" tag_type="text">However, the use of PA as a postexposure vaccine may be</text>
<text top="510" left="313" width="241" height="9" font="font4" id="p1_t90" reading_order_no="87" segment_no="9" tag_type="text">limited. Since PA is a natural component of anthrax toxin</text>
<text top="521" left="313" width="241" height="9" font="font4" id="p1_t91" reading_order_no="88" segment_no="9" tag_type="text">and may contribute to toxin formation, it may not be safe</text>
<text top="533" left="313" width="241" height="9" font="font4" id="p1_t92" reading_order_no="89" segment_no="9" tag_type="text">to administer a PA-based vaccine to persons who have</text>
<text top="545" left="313" width="241" height="9" font="font4" id="p1_t93" reading_order_no="90" segment_no="9" tag_type="text">been or are suspected of having been exposed to anthrax.</text>
<text top="557" left="313" width="241" height="9" font="font4" id="p1_t94" reading_order_no="91" segment_no="9" tag_type="text">We recently proposed the replacement of PA in vaccines</text>
<text top="568" left="313" width="241" height="9" font="font4" id="p1_t95" reading_order_no="92" segment_no="9" tag_type="text">with a dominant-negative inhibitor (DNI) of anthrax</text>
<text top="580" left="313" width="241" height="9" font="font4" id="p1_t96" reading_order_no="93" segment_no="9" tag_type="text">toxin [57]. DNI is a translocation-deficient mutant of PA</text>
<text top="592" left="313" width="241" height="9" font="font4" id="p1_t97" reading_order_no="94" segment_no="9" tag_type="text">carrying double mutations of K397D and D425K and has<a href="">[33,39,42,52,53]. Aft</a>er a naturally acquired infection, and</text>
<text top="604" left="313" width="241" height="9" font="font4" id="p1_t98" reading_order_no="95" segment_no="9" tag_type="text">been demonstrated to interfere with the intoxication proc-</text>
<text top="615" left="313" width="241" height="9" font="font4" id="p1_t99" reading_order_no="96" segment_no="9" tag_type="text">ess, providing immediate therapeutic protection against</text>
<text top="627" left="313" width="241" height="9" font="font4" id="p1_t100" reading_order_no="97" segment_no="9" tag_type="text">anthrax toxin in vivo [58,59]. Furthermore, when used as</text>
<text top="639" left="313" width="216" height="9" font="font4" id="p1_t101" reading_order_no="98" segment_no="9" tag_type="text">a vaccine, DNI is more immunogenic than PA [57].<a href="">ed [34,54-56]. Inte</a>restingly, antibodies to the cap-</text>
<text top="662" left="313" width="241" height="9" font="font4" id="p1_t102" reading_order_no="99" segment_no="10" tag_type="text">The symptoms and incubation period of human anthrax<a href="">% cases [55,56], wherea</a>s no</text>
<text top="674" left="313" width="241" height="9" font="font4" id="p1_t103" reading_order_no="100" segment_no="10" tag_type="text">vary depending on the route of transmission. The reported</text>
<text top="686" left="313" width="241" height="9" font="font4" id="p1_t104" reading_order_no="101" segment_no="10" tag_type="text">incubation period of inhalational anthrax, the most lethal</text>
<text top="698" left="313" width="241" height="9" font="font4" id="p1_t105" reading_order_no="102" segment_no="10" tag_type="text">form, ranges from 1 to 43 days [60]. Data from animal</text>
<text top="709" left="313" width="241" height="9" font="font4" id="p1_t106" reading_order_no="103" segment_no="10" tag_type="text">studies suggest that anthrax spores persist in the host for<b>Further improvement: two-in-one postexposure </b></text>
<text top="721" left="313" width="241" height="9" font="font4" id="p1_t107" reading_order_no="104" segment_no="10" tag_type="text">several weeks after infection and that antibiotics can<b>antitoxic therapy/vaccine</b></text>
</page>
</pdf2xml>
